Suchergebnisse - "Gallagher, Rosa I"

PubPharm (37)

1

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Albain, K. | Yau, C. | Petricoin, E. | +46

2

Protein signaling and drug target activation signatures to guide therapy prioritization : Therapeutic resistance and sensitivity in the I-SPY 2 Trial

enthalten in: Cell reports. Medicine | 2023

von Gallagher, R. | Wulfkuhle, J. | Wolf, D. | +25

3

Establishment and characterization of patient-derived xenograft of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion

enthalten in: Scientific reports | 2023

von Damayanti, N. | Saadatzadeh, M. | Dobrota, E. | +19

4

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer

enthalten in: NPJ breast cancer | 2023

von Elias, A. | Spoelstra, N. | Staley, A. | +20

5

Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors

enthalten in: Cancers | 2022

von Pandya, P. | Jannu, A. | Bijangi-Vishehsaraei, K. | +26

6

Redefining breast cancer subtypes to guide treatment prioritization and maximize response : Predictive biomarkers across 10 cancer therapies

enthalten in: Cancer cell | 2022

von Wolf, D. | Yau, C. | Wulfkuhle, J. | +31

CommentIn: Cancer Cell. 2022 Jun 13;40(6):592-594. - PMID 35700705

7

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Shi, Z. | Wulfkuhle, J. | Nowicka, M. | +15

CommentIn: Expert Rev Mol Diagn. 2023 Jul-Dec;23(12):1057-1059. - PMID 37902050

8

Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer : a prospective phase II clinical trial

enthalten in: Molecular oncology | 2022

von Pierobon, M. | Robert, N. | Northfelt, D. | +22

9

Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer : a prospective phase II clinical trial

enthalten in: Molecular Oncology | 2022

von Pierobon, M. | Robert, N. | Northfelt, D. | +22

10

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

enthalten in: Nature communications | 2021

von Clark, A. | Yau, C. | Wolf, D. | +48